Dorra Bouazzi

Dorra Bouazzi

Auto-generated profile, based on publicly available information

Dorra Bouazzi

Department of Dermatology, Zealand University Hospital, Roskilde, Denmark

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 February 2024 in Dermatology
Verified
Journal Article
Closed access
PDF file
DBDorra Bouazzi
Dorra Bouazzi
RARune Kjærsgaard Andersen
Rune Kjærsgaard Andersen
GVGabrielle R. Vinding
Gabrielle R. Vinding
CMCecilia E. Medianfar
Cecilia E. Medianfar
SNSabrina Mai Nielsen
Sabrina Mai Nielsen
GJGregor B.E. Jemec
Gregor B.E. Jemec
Introduction: Data concerning the global burden of hidradenitis suppurativa (HS) are limited. Reported prevalence estimates vary between 0.0003% and 4.1%, and data from various geographical regions are still to be collected. Previously reported prevalences have been limited by the methodological approach and source of data. This has resulted in great heterogeneity as prevalence data from physician-diagnosed cases poorly match those of self-reported apparent HS disease. Methods: The Global Hidradenitis Suppurativa Atlas (GHiSA) introduces an innovative approach to determine the global prevalence of HS. This approach involves using a previously validated questionnaire to screen apparently healthy adults accompanying a patient to a non-dermatological outpatient clinic visit in a hospital or a private/family medicine clinic. The screening questionnaire (i.e., the index test) is combined with a subsequent physician-based in-person validation (i.e., the reference standard) of the participants who screen positive. Approximately ten percent of the screen-negative participants are also clinically assessed to verify the diagnostic precision of the test. The local prevalence (pi) will be estimated from each country that submits the number of patients who are HS positive according to the index test and clinical examination (n), and the corresponding total number of observations (N). Conclusion: The GHiSA Global Prevalence studies are currently running simultaneously in 58 countries across six continents (Africa, Europe, Australia, North America, South America, and Asia). The goal of the combined global proportion is the generation of a single summary (i.e., proportional meta-analysis), which will be done after a logit transformation and synthesized using a random-effects model. The novel standardization of the Global Prevalence Studies conducted through GHiSA enables direct international comparisons, which were previously not possible due to substantial heterogeneity in past HS prevalence studies.

1 July 2022 in American Journal of Clinical Dermatology
Verified
Journal Article
Closed access
PDF file
MHMattias A. S. Henning
Mattias A. S. Henning
DBDorra Bouazzi
Dorra Bouazzi
GJGregor B. E. Jemec
Gregor B. E. Jemec

11 February 2020 in Dermatologic Surgery
Verified
Journal Article
Closed access
DBDorra Bsc Bouazzi
Dorra Bsc Bouazzi
LCLana Chafranska
Lana Chafranska
DSDitte Marie Lindhardt Saunte
Ditte Marie Lindhardt Saunte
GJGregor Borut Ernst DmSc Jemec
Gregor Borut Ernst DmSc Jemec
BACKGROUND: The possible connection between hidradenitis suppurativa (HS) patients undergoing surgery and higher complications/recurrences has been implied, but inconsistent results reported. OBJECTIVE: To assess the complication and recurrence rates for HS patients undergoing surgery and to evaluate whether known HS comorbidities and habits (smoking, obesity and diabetes) have an effect on the complication and recurrence rates. MATERIALS AND METHODS: A systematic review was conducted by 2 reviewers. PubMed and Embase were searched using a predefined search string created in collaboration between the authors and a librarian on January 23, 2019. RESULTS: Of the 271 references in the original search, 54 relevant articles were identified. This systematic review indicates an overall mean complication rate of 24% and a mean recurrence rate of 20.1% for HS patients undergoing surgery. CONCLUSION: No significant association between the known surgical risk factors and surgical complications—or recurrence rates in this patient group was found. This review revealed a lack of quality and quantity data in studying the complications/recurrences. The heterogeneity of the studies created limitations, and the presented mean complication/recurrence rates should be interpreted with the consequences thereof. It elucidates the need for better studies and a necessity for a standardized definition of postsurgical HS recurrence.

10 January 2023 in Acta Dermato-Venereologica
Verified
Journal Article
Open access
PDF file
SBSofia Hedvig Christina Botvid
Sofia Hedvig Christina Botvid
LHLone Storgaard Hove
Lone Storgaard Hove
DBDorra Bouazzi
Dorra Bouazzi
RARune Kjærsgaard Andersen
Rune Kjærsgaard Andersen
STSimon Francis Thomsen
Simon Francis Thomsen
GJGregor B.E. Jemec
Gregor B.E. Jemec
Is missing (Short communication)

1 October 2022 in British Journal of Dermatology
Verified
Journal Article
Closed access
PHPaa Gyasi Hagan
Paa Gyasi Hagan
DBDorra Bouazzi
Dorra Bouazzi
GNGideon Nyarko
Gideon Nyarko
EDElsie Serwaa Dartey
Elsie Serwaa Dartey
KNKojo Botsie Nunoo-Ghartey
Kojo Botsie Nunoo-Ghartey
GJGregor B.E. Jemec
Gregor B.E. Jemec

16 August 2023 in Biomedicines
Verified
Journal Article
Open access
PDF file
ELEdyta Lelonek
Edyta Lelonek
DBDorra Bouazzi
Dorra Bouazzi
GJGregor B. E. Jemec
Gregor B. E. Jemec
Jacek C. SzepietowskiJacek C. Szepietowski
Jacek C. Szepietowski
Hidradenitis suppurativa (HS) is a chronic skin disease that significantly impairs the quality of life of affected individuals. The disease is characterized by persistent purulent lesions in specific anatomical areas, and its pathophysiology involves multiple factors, including inflammation, genetics, the microbiome, and environmental components. Recent research suggests a potential role for pathogenic bacteria in HS, highlighting the importance of the communication between the human host and the microbiome in maintaining homeostasis and immune system reactivity. However, the exact mechanisms underlying the gut–skin microbial interactions in HS remain unclear. This systematic review aims to examine the existing literature on the differences in skin and gut microbiome composition between HS patients and healthy controls. The review identifies methodological inconsistencies and calls for further research to elucidate the microbiome’s role in HS pathogenesis and to explore new therapeutic interventions. The review highlights the need for advancements in microbiome research methodologies, such as metataxonomics and metagenomics, to improve our understanding of the microbiota’s impact on health and disease.